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Snakebites are a public health problem, especially in tropical countries.However, treatmentwith antivenomhas limited effectiveness
against venoms’ local effects. Here, we investigated the ability of Abarema cochliacarpos hydroethanolic extract (EAc) to protect
mice against injection of Bothrops leucurus venom. Swiss mice received perimuscular venom injection and were subsequently
treated orally with EAc in different doses. Treatment with EAc 100, 200, and 400mg/kg reduced the edema induced by B. leucurus
in 1%, 13%, and 39%, respectively. Although lower doses showed no antihypernociceptive effect in the Von Frey test, the higher
dose significantly reduced hyperalgesia induced by the venom. Antimyotoxic activity of EAc was also observed by microscopy
assessment, with treated muscles presenting preserved structures, decreased edema, and inflammatory infiltrate as compared to
untreated ones. Finally, on the rotarod test, the treated mice showed better motor function, once muscle fibers were preserved
and there were less edema and pain. Treated mice could stand four times more time on the rotating rod than untreated ones. Our
results have shown that EAc presented relevant activities against injection of B. leucurus venom in mice, suggesting that it can be
considered as an adjuvant in the treatment of envenomation.
1. Introduction
Accidents with venomous snakes represent a significant
health problem, especially in tropical countries, where
they frequently affect young and economically active men
working in the countryside. In Brazil, most accidents are
caused by snakes belonging to Bothrops genus, which induce
extensive local damage, such asmyonecrosis and edema [1, 2].
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Particularly, the snake Bothrops leucurus is present in the
Northeastern region of Brazil [3], being related to accidents
with rural workers who often have difficult access to health
services to receive the antiophidic treatment proposed by the
Health Ministry, that is, the antibothropic antivenom.
Antibothropic antivenom is the only official treatment
available, but it has low and limited effectiveness against the
local effects of venoms [1]. The antivenom therapy is often
applied late after the accident, when tissue destruction is
already in process, potentially causing irreversible and dis-
abling damage [4–6]. The use of plants and other alternative
approaches to halt the effect of snake venoms or to accelerate
tissue recovery has been proposed by previous studies [7–11].
Therefore, our group has been particularly concerned with
the search for new and effective pharmacologically active
principles from plants used in folk medicine to treat or
prevent damage caused by accidents with venomous snakes.
Many traditional communities of northeastern Brazil
make use of the bark of Abarema cochliacarpos in popular
medicine. A. cochliacarpos is an ornamental tree native to
Brazil, occurring mainly in the Atlantic Forest and in the
Caatinga biomes. It belongs to the Mimosaceae family, being
popularly known as “barbatima˜o” [12, 13]. An ethnophar-
macological survey accomplished in a rural community in
the Caatinga in the state of Sergipe, northeastern Brazil,
identified popular applications of the bark ofA. cochliacarpos
[12]. In this community, the decoction of the bark is used
to wash external ulcers while its tincture, made by placing
the bark in the Brazilian beverage known as “cachac¸a,”
is used against inflammation and gastric ulcers, among
other uses [12, 13]. Other authors also observed similar
applications in different traditional communities [14, 15].
According to previous studies, the hydroethanolic extract
presents phenolics such as aurones, catechins, chalcones,
flavanols, flavones, flavonols, leucoanthocyanidins, tannins
and xanthones, besides saponins, and steroids [16].
In our study, we assessed the antiophidic ability of A.
cochliacarpos extract, in order to propose a new option for the
treatment of envenoming, besides the antivenom, by using a
plant that is abundant in Brazil, and compared the extract
activity with dexamethasone, a steroidal anti-inflammatory
drug previously described to be active against some Bothrops
venoms effects [11].
2. Material and Methods
2.1. Material. B. leucurus snake venom was obtained
from CEPLAC (Comissa˜o Executiva do Plano da Lavoura
Cacaueira, Bahia, Brazil). B. leucurus venom and hydroeth-
anolic extract of A. cochliacarpos were dissolved in
physiological saline solution (PSS); PSS was composed
of (mM) NaCl, 135; KCl, 5; CaCl
2
, 2; MgCl
2
, 1; NaHPO
4
, 1;
NaHCO
3,
15, and dextrose, 11. The pH of this solution was
equilibrated to 7.3 with 5% CO
2
/95% O
2
. Dexamethasone
was obtained from Ache´ (Sa˜o Paulo, Brazil).
2.2. Plant Material and Extract Preparation. Abarema cochli-
acarpos (Gomes) Barneby & Grimes stem barks were
collected in Sa˜o Cristo´va˜o, state of Sergipe, Brazil (230m,
11∘01󸀠63.2󸀠󸀠 south, 37∘15󸀠86.6󸀠󸀠 west). The plant material was
identified by Dr. Ana Paula Prata and a voucher specimen
was deposited at the herbarium of the Federal University
of Sergipe under the number ASE 014639. Plant material
(5 kg) was dried at 37∘C with air circulation and renewal
until complete dehydration. Then, it was reduced to powder
and subsequently subjected to extraction in 90% ethanol
for 5 days with exhaustive maceration. After this period,
the extract was filtered and concentrated in a rotary evap-
orator under reduced pressure at 50∘C yielding 533.4 g of
hydroethanolic extract. The phytochemical analysis of A.
cochliacarposhas been recently performed anddescribed [16].
2.3. Animals. Male Swiss mice (25.0 ± 5.0 g), 2-3 months of
age, were used throughout this study. The animals originated
from the Central Animal Care of the Federal University of
Sergipe. The animals were randomly housed in appropriate
cages at 22 ± 2∘C on a 12 h light/dark cycle with free access to
food andwater. Experimental protocols were approved by the
Animal Care and Use Committee (CEPA/UFS number 10/11)
at the Federal University of Sergipe.
2.4. Experimental Design. Mice were divided into six
groups of 6 animals. They were anesthetized with ketamine
(100mg/kg) and xylazine (10mg/kg) and then injected
with crude venom of Bothrops leucurus (BlV) 1.0mg/kg in
PSS by applying 50𝜇L of the solution next to the extensor
digitorum longus (EDL) muscle of the right hind limb (EDL
perimuscular injection, in order to prevent direct mechanical
damage to the muscle), as described previously [9, 17]. Mice
treated with A. cochliacarpos received administration by oral
gavage.
Group I (control group). Mice were not subjected to muscle
injury induced by venom and instead they received PSS in
order to check for any changes in the parameters analyzed.
Group II (BlV group).Mice received 1.0mg/kg of B. leucurus
venom injection (50 𝜇L) into the right paw.
Group III (BlV + Dexamethasone – Dexa). Five minutes after
venom injection, intravenous dexamethasone (2mg/kg) was
administered.
Group IV (BlV + EAc 100mg/kg). Five minutes after venom
injection, mice received hydroethanolic extract of A. cochli-
acarpos by oral gavage (EAc, 100mg/kg in 100 𝜇L).
Group V (BlV + EAc 200mg/kg). Five minutes after venom
injection, mice received hydroethanolic extract of A. cochli-
acarpos by oral gavage (EAc, 200mg/kg in 100 𝜇L).
Group VI (BlV + EAc 400mg/kg). Five minutes after venom
injection, mice received hydroethanolic extract of A. cochli-
acarpos by oral gavage (EAc, 400mg/kg in 100 𝜇L).
2.5. Edematogenic Activity. The induction of edema was
evaluated in all groups. Measurements were made at 0, 15, 30,
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Figure 1: Effect of A. cochliacarpos extract (EAc) on B. leucurus venom’s edematogenic activity.Mice received perimuscular injection of PSS
or B. leucurus venom (1mg/kg). The animals were treated with oral EAc at 100mg/kg, 200mg/kg, and 400mg/kg and i.v. dexamethasone
(2mg/kg) 5min after venom injection. Results show hind limb edema measured with a caliper rule until 90 minutes after venom injection
(panel (a)). Panel (b) shows the area under the curve analysis with the data observed in (a). Data report means ± SEM (𝑛 = 6). ∗𝑃 < 0.05
versus venom group (Student’s 𝑡-test).
60, and 90min after venom injection. An analog caliper rule
was used to measure the mediolateral and anteroposterior
widths of the paw, and the product of these values is reported
as mm2.
2.6. Motor Functional Activity: Rotarod Test. Motor activity
was assessed using the rotarod test to analyze the riding time
as previously described [9]. The mice were trained daily for
a period of 120 s for 5 days on the rotating cylinder (8 rpm)
(Rota Rod EFF 412, Insight, Ribeira˜o Preto, SP, Brazil). One,
three, and seven days after injection of 1.0mg/kg venom
alone or with treatments, the animals were submitted to the
rotarod test and the time spent by the animal on the apparatus
was recorded. Each animal underwent three trials, with an
interval of at least 2 h for all animals, and themean time spent
on the rod was determined for each group.
2.7. Hyperalgesia Induced by B. leucurus Venom. Mechanical
sensation of the hind paw as an index of mechanohyper-
algesia test was assessed by pressure stimulation method
(Von Frey modified method), as described by Mogil et
al. [18]. Briefly, the nociceptive threshold was measured at
different times after venom injection and treatments using
an electronic anesthesiometer (EFF 301, Insight, Ribeira˜o
Preto, SP, Brazil). A force (in g) of increasing magnitude was
applied to the paw.When the animals reacted bywithdrawing
the paw, the force needed to induce such response was
recorded and represented the nociceptive threshold.
2.8. Myotoxicity In Vivo. We evaluated the myotoxicity of
B. leucurus venom by measuring the increase of plasma
creatine kinase (CK) activity induced by intramuscular (i.m.)
injection of venom alone or followed by i.v. dexamethasone
or different doses of A. cochliacarpos extract by oral gavage.
The venom was dissolved in PSS to a final volume of 0.1mL
(1.0mg/kg) and they were injected into the rear thigh of the
mice. Negative controls consisted of mice injected with the
same volume of PSS.
2.9. Muscle Damage Histological Analysis
2.9.1. Light Microscopy. Twenty-four hours after the venom
injection and respective treatments, the animals were killed
under anesthesia with ethyl ether; their EDL muscles were
gently removed, fixed in standard paraformaldehyde, embed-
ded in paraffin, longitudinally sectioned, and stained with
hematoxylin and eosin (HE) for light microscopy analysis.
2.9.2. Scanning Electron Microscope (SEM). Some mice had
their EDL muscles studied by scanning electron microscopy
after the removal of connective tissue matrices using col-
lagenase. Muscles were rinsed twice in physiological buffer
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Figure 2: Effect of A. cochliacarpos extract (EAc) on B. leucurus
venom’s mechanical hyperalgesia response.Mice received perimus-
cular injection of PSS or B. leucurus venom (1mg/kg). The animals
were treated with oral EAc at 100mg/kg, 200mg/kg, and 400mg/kg
and i.v. dexamethasone (2mg/kg) 5min after venom injection.
Results showing the force needed to cause paw withdraw (pain
threshold). Data report means ± SEM (𝑛 = 6). ∗𝑃 < 0.05 and
∗∗
𝑃 < 0.01 versus venom group (Student’s 𝑡-test).
solution (PBS) and fixed in 2.5% glutaraldehyde and 2%
paraformaldehyde in phosphate buffer (0.1M, pH 7.4)
overnight at room temperature. After being washed three
times in PBS, samples were fixed in 1% osmium tetroxide
in aqueous solution (pH 7.4) at 4∘C for 1 h. They were
then dehydrated, dried in a critical point dryer (CPD 030,
Balzers, Ribeira˜o Preto, SP, Brazil), and gold-sputtered (SCD
040, Balzers, Ribeira˜o Preto, SP, Brazil). Scanning electron
microscope (SEM) images were taken on a LEO 435 VP
SEM, 30 kV used to image capture (Carl Zeiss, Oberkochen,
Germany).
2.10. Statistical Analysis. Data were expressed as mean ±
SEM, and Student’s t-test was used for statistical analysis.The
𝑃 values <0.05 and <0.01 were used to indicate a significant
difference between means.
3. Results
The venom of B. leucurus (1.0mg/kg) showed edematogenic
effect after perimuscular injection (Figure 1(a)). Fifteen
minutes after injection, the venom induced a variation in
leg area of 27.97 ± 2.44mm2, while in the control group
the variation caused by the injection of PSS was of only
4.10 ± 0.59mm2. The limb edema induced by the venom
was partially inhibited by increasing doses ofA. cochliacarpos
∗
∗
∗
∗
120
100
80
60
40
20
0 1 3 7
Ti
m
e o
n 
ro
ta
ro
d 
(s
)
Time (days)
Control
BIV
BIV + EAc 100mg/kg
BIV + EAc 200mg/kg
BIV + EAc 400mg/kgBIV + Dexa
Figure 3: Functional activity. Time spent by mice on the rotarod
(8 rpm) before and after receiving B. leucurus venom (1.0mg/kg).
The animals were treated with oral EAc at 100mg/kg, 200mg/kg,
and 400mg/kg and i.v. dexamethasone (2mg/kg) 5min after venom
injection. Time zero represents data obtained before venom injec-
tion. Data report means ± SEM (𝑛 = 6). ∗𝑃 < 0.05 versus venom
group (Student’s 𝑡-test).
extract and by dexamethasone (Figures 1(a) and 1(b)). Treat-
ment with dexamethasone (2.0mg/kg) reduced the overall
edema in 52%,while 100, 200, and 400mg/kgA. cochliacarpos
extract reduced the edema induced by B. leucurus in 1%, 13%,
and 39%, respectively (Figure 1(b)).
The injection of BlV (1mg/kg) into the mice hind
limbs caused a significant decrease in nociceptive threshold
(hyperalgesia), besides the increase in limb volume. In our
protocol, the peak of the hypernociceptive response occurred
2 h after venom injection, and after this time the phenomenon
started to decrease and completely disappeared at 24 h (data
not shown). When animals were treated with 400mg/kg A.
cochliacarpos extract or with dexamethasone, the hyperal-
gesic response was significantly reduced. Lower doses of the
extract showed no antihyperalgesia effect (Figure 2).
After B. leucurus venom injection, all animals, including
those receiving treatment, showed a decrease in functional
ability to stand on the rotarod. However, on the first and
third days after injection, mice receiving venom only or
venom treated with 100mg/kg and 200mg/kg EAc showed
a more pronounced decrease, compared to animals treated
with Dexa or 400mg/kg EAc. This result shows that EAc
decreased the impact of venom on motor functional activity.
By day 7, all animals, including those that received only
venom injection without any treatment, were able to stand
on the rotarod as long as the control mice, showing recovered
muscle function (Figure 3).
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Figure 4: In vivo myotoxicity. The figure shows the effect of EAc
and dexamethasone on B. leucurusmyotoxic activity in vivo. Results
show plasma CK activity 2 hours after injection of the venom alone
or followed by treatment with i.v. dexamethasone or EAc by oral
gavage. Data report means ± SEM (𝑁 = 5). ∗𝑃 < 0.05 for the
difference between treated groups and the venom (Student’s 𝑡-test).
Mice injected intramuscularly with the venom of B. leu-
curus (1mg/kg) presented, 2 hours after venom injection, an
increased activity of CK in plasma, which ranged from 127.75
± 1.59U/L (𝑛 = 5) in the group receiving the PSS solution
up to 877.70 ± 21.54U/L (𝑛 = 5) in the group receiving the
venom.Oral treatment ofmicewith the different doses of EAc
partially inhibited the in vivomyotoxic activity of the venom
(Figure 4).
Light microscopy of the EDL muscles 24 h after injection
of B. leucurus venom showed structural disorganization of
muscle fibers with cellular damage and inflammatory cellular
infiltration, characteristics of a typical inflammatory reaction.
Treatment with 400mg/kg A. cochliacarpos extract and with
dexamethasone preserved the muscle fibers and seemed to
reduce the presence of inflammatory cells (Figure 5).
Ultrastructural study of EDLmuscle fibers confirmed the
observations of light microscopy (Figure 6). Control muscles
injected with PSS had a constant diameter of about 20𝜇m
and showed long cylindrical forms, occasionally splitting or
dividing to provide branches within the muscle (Figure 6(a)).
On the other hand, in the muscles injected with B. leucurus
venom (1.0mg/kg), focal areas ofmyonecrosis were abundant
after 24 h. Injured fibers presented dilated perimysium and
disoriented and condensedmyofibrils (Figures 6(b) and 6(c)).
Furthermore, as shown in Figure 6(d), hemorrhage was
apparent in the endomysial connective tissue, and hemolysis
was discernible. Degeneration was pronounced in areas
where the erythrocytes were tightly packed between the
muscle fibers. Myofibrils were hypercontracted leaving, as
a consequence, areas of overstretched myofibrils as well as
empty spaces. On its turn, muscles of mice treated with i.v.
dexamethasone showed no damage or extensive hemorrhage
(Figure 6(e)). Finally, the oral administration ofA. cochliacar-
pos hydroalcoholic extract (400mg/kg) also decreased the
myonecrotic effect of B. leucurus venom, with fewer areas of
hypercontracted myofilaments or hemorrhagic components
(Figure 6(f)).
4. Discussion
Our study confirmed the ability of Bothrops leucurus venom
injection to induce muscle damage, edematogenic activity,
hyperalgesia, and motor function impairment. Among the
important components of this venom are several metallo-
proteinases and phospholipases A
2
(PLA
2
), which present
cytotoxic and proinflammatory properties [3, 19–23]. Our
results provide for the first time an experimental and scien-
tific support for the use of A. cochliacarpos extractin cases
of accidents with B. leucurus snake venom,which had some
important activities inhibited in experimental conditions by
the plant’s crude extract.
Edema is an important effect of Bothrops venoms, which
along with tissue necrosis can be severe enough to cause
functional loss or even compartment syndrome [24]. As part
of the classical inflammatory reaction, the edema generation
was rapidly set following venom injection. Venom-induced
edema has been described as an inflammatory process
induced by components that involve local mediators derived
from arachidonic acid and autacoids such as histamine and
serotonin and is not substantially antagonized by antivenom
[25, 26], constituting a major complication related to acci-
dents caused by Bothrops in large animals. In agreement with
previous studies [11, 27], the anti-inflammatory properties
of dexamethasone were able to partially inhibit the edema
induced by venom injection, strongly supporting that at
least in part the venom activity depends on inflammation.
Interestingly, the crude extract of A. cochliacarpos was also
able to reduce the edematogenic effect of B. leucurus venom
injection, confirming early observations showing that this
plant presents some anti-inflammatory properties [16, 28–31].
Inflammation is frequently associated with pain and
hypernociception [32, 33]. Inflammatory hyperalgesia follows
alterations in transduction sensitivity in the peripheral termi-
nals (nociceptors) and in excitability in the central nervous
system. Such alterations are secondary to the activation
of chemosensitive nociceptors by inflammatory mediators,
which are extensively induced by snake venom injection
[33–35]. It has been shown that hyperalgesia induced by
Bothrops sp. venoms is not neutralized when antivenoms
are administered after envenomation [35], and the clin-
ical relevance of pain following envenomation points to
the need to develop pain-controlling therapeutic strategies.
The known antihyperalgesic actions of dexamethasone [36]
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Figure 5: Light microscopy of mouse EDL muscle 24 h after perimuscular injection of B. leucurus venom: effect of A. cochliacarpos extract
(EAc). Longitudinal sections stained with hematoxylin and eosin: (a) PSS; (b) venom (1.0mg/kg); (c) venom + dexamethasone (2mg/kg, i.v);
(d) venom + EAc 100mg/kg; (e) venom + EAc 200mg/kg; and (f) venom + EAc 400mg/kg (𝑛 = 6 per group). In panel (a), panoramic view
of control muscle showing normal multinucleated myofibers with peripheral nuclei (arrow) and no morphological changes. Panels (b), (d),
and (e) show necrotic myofibers in different stages of degeneration (arrowheads), edema between the fibers (stars) and intense inflammatory
infiltrate (asterisks) that reaches the internal portions of the muscle. In (c) and (f), observe preserved muscle fibers with peripheral nuclei
(arrows). We can see some inflammatory cells (diagonal arrows) and small vacuoles (lozenges). Magnification: 40x.
were confirmed in our study. Again, oral administration of
A. cochliacarpos extract successfully decreased the hyperal-
gesic action of B. leucurus venom.
As previously shown, i.m. injection of the Bothrops
venoms induces extensive myonecrosis in mice [37–42]. Our
study showed the important in vivomyotoxicity ofB. leucurus
venom, which was decreased by both dexamethasone and
A. cochliacarpos extract, as well as the plasma CK activity
induced by the venom. This is of great importance consider-
ing the high myotoxicity of Bothrops venoms and the lack of
protection from this activity by the available treatment, the
antibothropic antivenom, leading to functional disabilities
due to poor muscle regeneration [43].
Local and systemic skeletal muscle degeneration is a
common consequence of envenomations due to snakebites.
PLA
2
s are important myotoxic components in Bothrops
venoms, inducing a similar pattern of degenerative events in
muscle cells. Myotoxic PLA
2
s bind to acceptors in the plasma
membrane, which might be lipids or proteins and which may
differ in their affinity for the PLA
2
s. Upon binding, myotoxic
BioMed Research International 7
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Figure 6: The cytoarchitecture of mouse EDL muscle 24 h after perimuscular injection of B. leucurus venom: effect of A. cochliacarpos
extract (EAc). Muscles were studied by scanning electron microscopy after the removal of connective tissue matrices using a modified KOH-
collagenase digestion method. (a) PSS; (b), (c), and (d) venom (1.0mg/kg); (e) venom + dexamethasone (2mg/kg, i.v); (f) venom + EAc
400mg/kg (𝑛 = 6 per group). Magnification: 100x ((a), (b), (e), and (f)); 400x ((c) and (d)).
PLA
2
s disrupt the integrity of the plasma membrane by
catalytically dependent or independent mechanisms, pro-
voking a pronounced Ca2+ influx which, in turn, initiates
a complex series of degenerative events associated with
hypercontraction, activation of calpains and cytosolic Ca2+-
dependent PLA
2
s, and mitochondrial Ca2+ overload [6, 44].
Our experiments showed dose-dependent inhibition of B.
leucurusmyotoxic activity by A. cochliacarpos extract, which
could be related to inhibition of the venom’s PLA
2
s, besides
decreasing muscle damage by the inflammatory reaction
itself.
Finally, mice receiving treatment with dexamethasone
or A. cochliacarpos extract showed better functional per-
formance, that is, because the morphological and biochem-
ical properties seemed to be preserved, and once edema
and hypernociception were to some extent prevented, their
physical activity was superior to that achieved by untreated
animals. Although in morphological analysis we did not
measure the extent of the damaged area or the number of
centrally located nuclei, this qualitative demonstration of the
positive effects of A. cochliacarpos extract was confirmed by
rotarod performance and the decreased plasma CK activity.
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Several groups have demonstrated potential therapeu-
tic uses of A. cochliacarpos, such as protective effects in
acute experimental colitis [28], gastroprotective effects and
wound-healing properties [29], and antioxidant and anti-
inflammatory properties [16, 31]. Those abilities have been
related to inhibition of oxidative stress and inflammatory
responses via direct downregulation of nitric oxide (NO)
and reactive oxygen species (ROS) generation, which could
damage different cellular components such as lipids, proteins,
and DNA.The antioxidant and anti-inflammatory properties
of A. cochliacarpos hydroethanolic extract may be mediated,
at least in part, by the presence of (+)-catechin, a flavonoid-
type compound, the most abundant in the extract, which
induce downregulation of proinflammatory cyclooxygenase-
2 (COX-2) and inducible nitric oxide synthase (iNOS)
enzymes [16, 28, 29, 31].
5. Conclusion
Our results have shown the antiophidic ability of A. cochli-
acarpos extract, which seem to be related to its antioxidant,
antihyperalgesic, and anti-inflammatory properties, for the
first time giving scientific support for its use in folk medicine
as an adjuvant to the available antivenom therapeutics.
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